Pharmanutra
Pharmanutra S.p.A., a leading name in the pharmaceutical preparation manufacturing industry, is headquartered in Italy and operates extensively across Europe and beyond. Founded in 2003, the company has established itself as a pioneer in the development of innovative nutritional supplements and medical devices, particularly those based on iron and mineral formulations.
Pharmanutra's core products, including the renowned SiderAL® line, are distinguished by their unique formulations that enhance bioavailability and absorption, setting them apart in a competitive market. With a commitment to research and development, the company has achieved significant milestones, including numerous patents and collaborations with healthcare professionals.
Recognised for its quality and efficacy, Pharmanutra continues to strengthen its market position, contributing to advancements in health and wellness through scientifically-backed solutions.
-5 vs industry average
Pharmanutra’s score of 34 is lower than 48% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Pharmanutra?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Pharmanutra's reported carbon emissions
Pharmanutra, an Italian pharmaceutical preparation manufacturer, has disclosed its carbon emissions for several years.
In 2024, the company reported a total of approximately 3.7 million kg CO2e. This figure comprises Scope 1 emissions of about 220,000 kg CO2e and Scope 2 emissions of approximately 1.48 million kg CO2e. Scope 3 emissions were also reported, with fuel and energy-related activities contributing around 12,100 kg CO2e.
For 2023, Pharmanutra's total emissions were approximately 686,000 kg CO2e. Scope 1 emissions stood at about 229,000 kg CO2e, and Scope 2 emissions were approximately 457,000 kg CO2e. Fuel and energy-related activities within Scope 3 accounted for about 11,890 kg CO2e.
In 2022, total emissions were approximately 230,000 kg CO2e, with Scope 1 emissions at about 199,000 kg CO2e and Scope 2 emissions at approximately 89,000 kg CO2e.
Pharmanutra has been committed to disclosing its environmental impact. While specific reduction targets or achievements are not detailed in the provided information, the company has disclosed emissions data across Scope 1, 2, and 3 for recent reporting years, indicating a focus on understanding its carbon footprint within the pharmaceutical preparation manufacturing sector. The company's sustainability reports provide further details on its environmental performance.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Pharmanutra’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Pharmanutra yet.
Scope 3 top emissions categories
1 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Pharmanutra
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project